interim

NTG Nordic Transport Group publishes interim report for Q1 2025NTG Nordic Transport Group publishes interim report for Q1 2025

NTG Nordic Transport Group publishes interim report for Q1 2025

Company announcement no. 8 – 2512 May 2025 NTG Nordic Transport Group publishes interim report for Q1 2025 The interim…

1 week ago
Bavarian Nordic Announces Interim Results for the First Three Months of 2025Bavarian Nordic Announces Interim Results for the First Three Months of 2025

Bavarian Nordic Announces Interim Results for the First Three Months of 2025

COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress…

2 weeks ago
Late-Breaking Interim STENOVA Data Presented at Digestive Disease Week 2025 Demonstrate Potential of AGMB-129 in Fibrostenosing Crohns DiseaseLate-Breaking Interim STENOVA Data Presented at Digestive Disease Week 2025 Demonstrate Potential of AGMB-129 in Fibrostenosing Crohns Disease

Late-Breaking Interim STENOVA Data Presented at Digestive Disease Week 2025 Demonstrate Potential of AGMB-129 in Fibrostenosing Crohns Disease

Antwerp, Belgium, May 6, 2025 – Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA1 Phase…

2 weeks ago
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBCProtara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

April 26, 2025 10:00 ET  | Source: Protara Therapeutics TARA-002 demonstrates 100% complete response rate at any time and 67%…

3 weeks ago
Orion Group Interim Report JanuaryMarch 2025Orion Group Interim Report JanuaryMarch 2025

Orion Group Interim Report JanuaryMarch 2025

ORION CORPORATION INTERIM REPORT 1–3/2025 23 APRIL 2025 at 12:00 EEST Orion Group Interim Report January–March 2025 January–March 2025 Highlights…

4 weeks ago
iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity PipelineiBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as…

1 month ago
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing…

3 months ago
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

January 29, 2025 08:00 ET  | Source: 4D Molecular Therapeutics, Inc. Initial interim 52-week results from Phase 2b Population Extension…

4 months ago
Netcompany – Interim report for the 12 months ended 31 December 2024 and Annual Report 2024Netcompany – Interim report for the 12 months ended 31 December 2024 and Annual Report 2024

Netcompany – Interim report for the 12 months ended 31 December 2024 and Annual Report 2024

Company announcement No. 06/2025                                                  28 January 2025 Continued growth and margin improvement in a challenging marketSummary full year 2024…

4 months ago
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis BAssembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the…

5 months ago